Hyoscine butyl bromide (Hyoscini butylbromidum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

M-holinoblokatory

Included in the formulation
  • Buscopan®
    suppositories rect. 
    Boehringer Ingelheim International GmbH     Germany
  • Buscopan®
    pills inwards 
    Boehringer Ingelheim International GmbH     Germany
  • Neoscapan
    solution for injections 
    NOVOSIBHIMFARM, OJSC     Russia
    • АТХ:

    A.03.B.B.01   Hyoscine butyl bromide

    Pharmacodynamics:

    It blocks m-holinoretseptory, reducing the stimulating effect of acetylcholine: reduces the secretion of lacrimal, bronchial, sweat, gastric glands, as well as exocrine activity of the pancreas. As spasmolytic reduces the tone of the bile duct and gallbladder, the gastrointestinal tract, simultaneously increases the tone of the sphincters. Improves atrioventricular conductivity, causes tachycardia. It hinders the outflow of intraocular fluid, raises intraocular pressure, provokes paralysis of accommodation.

    Pharmacokinetics:

    After oral administration, an empty stomach is absorbed up to 8% in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 2 hours, after 5 minutes - after intravenous administration. The connection with plasma proteins is 4.4%.

    Metabolism in the liver.

    The half-life is 6 hours. Elimination with feces and kidneys.

    Indications:

    It is used to treat peptic ulcer of the stomach and duodenum.Used for cholelithiasis, biliary and renal colic, spasm of smooth musculature of the gastrointestinal tract, acute pancreatitis, dysmenorrhea, hemorrhoids and anus fracture.

    ICD-10

    XI.K20-K31.K25   Stomach ulcer

    XI.K20-K31.K26   Duodenal ulcer

    XI.K20-K31.K31.3   Pylorospasm, not elsewhere classified

    XI.K80-K87.K80   Gallstone disease [cholelithiasis]

    XI.K80-K87.K81.0   Acute cholecystitis

    XI.K80-K87.K81.1   Chronic cholecystitis

    XI.K80-K87.K82.8   Other specified diseases of the gallbladder

    XIV.N20-N23.N23   Renal colic, unspecified

    XIV.N80-N98.N94.5   Secondary dysmenorrhea

    XIV.N80-N98.N94.4   Primary dysmenorrhea

    XVIII.R10-R19.R10.4   Other and unspecified abdominal pain

    XI.K55-K63.K60.2   Anus fracture, unspecified

    XI.K94.K94 *   Diagnosis of diseases of the digestive tract

    XIV.N80-N98.N94.6   Dysmenorrhea, unspecified

    Contraindications:

    Keratoconus, irises of the iris, zakratougolnaya and open angle glaucoma, individual intolerance.

    Carefully:

    Ischemic heart disease, polyneuropathy, hypertension, diaphragmatic hernia, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.With prolonged use, suppresses lactation.

    Dosing and Administration:

    Use in children

    Intravenously slow, for emergency indications: 0.3-0.6 mg / kg to 12 years of age. The maximum daily dose is 1.5 mg / kg body weight.

    From 12 years: intravenously slowly, intramuscularly or subcutaneously for 20-40 mg (1-2 ampoules).

    Inside in children from 6 years old adult doses are used.

    Adults

    Inside, 10-20 mg 3-5 times a day.

    Rectally, 1-2 suppositories (10-20 mg) 3 times a day.

    Intravenously slowly, subcutaneously, intramuscularly, 20-40 mg (1-2 ampoules).

    The highest daily dose: 100 mg.

    The highest single dose: 40 mg.

    Side effects:

    Central and peripheral nervous system: dizziness, drowsiness, hallucinations, impairment tactile sensitivity.

    The cardiovascular system: tachycardia.

    Digestive system: dry mouth, constipation.

    Sense organs: mydriasis, paralysis of accommodation, photophobia.

    Urinary system: retention of urine.

    Allergic reactions.

    Overdose:

    Motion and speech excitation, impaired vision, drowsiness, unsteadiness of gait, hallucinations, oppression respiratory center.

    Treatment. The introduction of physostigmine (intravenously from 0.5 to 2 mg at a rate of up to 1 mg / min, not more than 5 mg per day) or neostigmine methyl sulfate (intramuscularly 1 mg every 2-3 hours,intravenously - up to 2 mg).

    Interaction:

    Antacids containing aluminum or calcium carbonate reduce the absorption of the drug in the gastrointestinal tract. It is recommended to maintain an interval of at least 1 hour.

    With simultaneous use with phenylephrine, the development of hypertension is possible.

    Reduces the concentration of levodopa in blood plasma, reduces or eliminates the effect of anticholinesterase drugs and m-cholinomimetics. Simultaneous use with atropine increases side effects.

    Special instructions:

    The use of the drug in conditions of high air temperature can provoke a heat stroke.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up